NCT03703375: A trial that was reported late by Celgene
This trial was previously reported as an Applicable Clinical Trial, but is no longer.
Full data
| Full entry on ClinicalTrials.gov | NCT03703375 |
|---|---|
| Title | Randomized Phase 3 Study Evaluation the Efficacy and Safety of Oral Azacitidine(CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma |
| Results Status | no-longer-act |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 6, 2018 |
| Completion date | Feb. 10, 2021 |
| Required reporting date | Feb. 10, 2022, midnight |
| Actual reporting date | Jan. 24, 2023 |
| Date last checked at ClinicalTrials.gov | Jan. 17, 2025 |
| Days late | 872 |